Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12579MR)

This product GTTS-WQ12579MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12579MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4886MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ3290MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ11903MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ11785MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ4239MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ4010MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ4048MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ10697MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW